Abstract 1564P
Background
With over 2 million cases diagnosed annually, breast cancer is a leading cause of cancer-related disability and mortality worldwide. Despite global efforts to implement screening programs, uptake rates vary widely across settings due to socioeconomic factors and accessibility challenges. In 2022 in Flanders (Belgium), breast cancer screening participation in municipalities with income below the poverty line was 15% lower than average.
Methods
To tackle the limited participation of low-SES women in the breast cancer screening program in Flanders, a culturally sensitive approach was used to realize a tailored reminder letter.
33 women (of which 29 non-native Dutch speakers) aged 50-69 with low-SES were identified with the assistance of community organizations to conduct Focus Group Discussions (FGDs). Through a series of 4 FGDs and 3 rounds of Delphi-consultations involving sector experts, valuable insights were gathered.
Results
Analysis of the standard invitation letter employed in the program revealed several challenges related to readability and comprehension. These included the excessive length of the text, the use of complex vocabulary and grammar beyond an A2 level, the inclusion of contextual sentences unrelated to the mammography appointment (“We do it. And what do you do?”), and the use of generic visuals (eg. a picture of women).
At the same time, simplifying the vocabulary to A1-A2 levels (“cancer”, “doctor”, “appointment”, “check”, “free”), employing straightforward sentence structures, and incorporating relevant visuals (e.g. image of a mammography machine) enhanced understandability and fostered interest in breast cancer prevention. Additionally, utilizing a color palette associated with breast cancer and featuring logos of local authorities instilled a sense of credibility and trustworthiness.
Conclusions
Based on feedback from sector experts and insights from the FGDs, a revised reminder letter was developed. The final communication was concise and included essential details such as time and place for screening, as well as a QR code providing translation into 12 languages.
To assess its efficacy in increasing participation rates, a RCT with 3,430 participants per arm is currently being conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting tegen Kanker.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10